Incyte Corp

2 nov. 2026, 20:26 UTC

Bernstein SocGen's Jeffrey Walch raises Incyte Corp's price target to $108.00 from $104.00 while maintaining a Market Perform rating.

30 oct. 2026, 23:16 UTC

Incyte Corp shares are modestly higher in after-market hours, remaining 5.89% above their 20-day moving average and near the upper end of their one-month range.

29 oct. 2026, 23:01 UTC

Incyte Corp is trading higher in after-market hours, reaching a high point and well above its 20-day moving average since Thursday's close.

28 oct. 2026, 20:07 UTC

Incyte Corp shares are advancing as investors monitor the Federal Reserve's decision to maintain interest rates amid rising inflation, despite an earlier pullback.

27 oct. 2026, 21:01 UTC

Incyte Corp shares declined in after-market trading after initially rising, reflecting significant volatility within the broader context of its one-month trading range.

26 oct. 2026, 21:01 UTC

Incyte Corp shares advanced modestly in after-market trading, maintaining a cumulative return of 0.83% since Monday's close.

23 oct. 2026, 20:07 UTC

Incyte Corp shares are declining amid a broader market downturn influenced by rising oil prices, inflation concerns, and geopolitical tensions.

22 oct. 2026, 20:07 UTC

Incyte Corp shares are advancing, continuing a notable upward trajectory since Wednesday's close, reaching their peak just before the close on Thursday.

21 oct. 2026, 20:07 UTC

Incyte Corp shares are declining, reflecting broader market weakness, and are approaching the low end of their one-month range amid a significant drop since Tuesday's close.

20 oct. 2026, 20:08 UTC

Morgan Stanley initiates coverage on Incyte Corp with an Equalweight rating and a price target of $119.00, following the stock's prior close of $113.25.

19 oct. 2026, 19:36 UTC

Incyte Corp will present new data on investigational therapies INCB161734 and INCA33890 at the ESMO Congress 2026, scheduled for October 23 to 27 in Madrid.

17 oct. 2026, 00:01 UTC

Incyte Corp shares are trading lower in after-market hours, reversing an initial gain and reaching their lowest point of the day.

16 oct. 2026, 20:13 UTC

Incyte Corp shares are modestly higher in after-market trading, maintaining a slight gain.

15 oct. 2026, 21:03 UTC

Incyte Corp shares are advancing in after-market trading, continuing a strong performance after three consecutive sessions of gains, though still below the 20-day moving average.

14 oct. 2026, 20:07 UTC

Truist Securities maintains Hold rating on Incyte Corp and raises price target to $115 in a report published today.

13 oct. 2026, 20:02 UTC

Incyte Corp shares fell sharply, reaching a low point shortly after the market opened and remaining below its 20-day moving average.

12 oct. 2026, 21:01 UTC

Incyte Corp shares declined in after-market trading, continuing a downward trend and remaining notably below its 20-day moving average.

9 oct. 2026, 20:07 UTC

Incyte Corp shares traded roughly flat, peaking at a cumulative return of 0.90%, but remain significantly below their 20-day moving average.

8 oct. 2026, 20:07 UTC

RBC Capital raised Incyte's price target to $114 and maintained its Sector Perform rating ahead of the company's Q3 results on October 29, 2026.

7 oct. 2026, 21:31 UTC

Incyte Corp is trading lower in after-market hours, closing at its lowest point of the day and below its 20-day moving average.

6 oct. 2026, 19:50 UTC

Incyte Corp shares fell sharply, extending a six-session decline amid notable volatility, with current prices significantly below the 20-day moving average.

5 oct. 2026, 21:01 UTC

Incyte Corp is down significantly in after-market trading, marking its seventh consecutive session lower and remaining well below its 20-day moving average.

2 oct. 2026, 23:05 UTC

Incyte Corp saw a modest increase in after-market trading, reaching its highest level since Friday's close, despite notable volatility during the session.

1 oct. 2026, 23:15 UTC

Incyte Corp declined in after-market hours, marking its fourth consecutive session of losses and remaining significantly below its 20-day moving average.

30 sept. 2026, 20:01 UTC

Incyte Corp shares fell sharply, remaining below their 20-day moving average and positioned near the lower end of their one-month range.

29 sept. 2026, 20:07 UTC

Incyte Corp's shares fell sharply, reaching a midday low and finishing weaker, remaining below their 20-day moving average and near the lower end of their one-month trading range.

28 sept. 2026, 21:01 UTC

Incyte Corp has advanced in after-market trading, reaching its highest level for the session amid broader biotechnology sector activity and remaining above its 20-day moving average.

25 sept. 2026, 19:36 UTC

Incyte shares fell after FDA approved Atebrioz for fibrodysplasia ossificans progressiva, as traders await clarity on the drug's commercial prospects.

24 sept. 2026, 22:01 UTC

Incyte Corp declined significantly in after-market trading, remaining well below its 20-day moving average and near the lower end of its one-month range.

23 sept. 2026, 20:07 UTC

Incyte Corp shares are declining, despite social media highlighting its strength in the biotechnology sector, reflecting a cumulative decline since Tuesday's close.